Solid Nutritional Composition Stability via Buffering Salt and Choline Bitartrate

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing solid compositions containing uridine, polyunsaturated fatty acids, and choline sources face stability issues during manufacturing, particularly with choline chloride's hygroscopicity and protein instability when combined with milk proteins, leading to phase separation, clumping, and poor reconstitution in powder forms.

Innovation Solution

A solid composition in powder form incorporating uridine, omega-3 fatty acids, choline bitartrate, a buffering salt component, and a milk protein source, specifically using skim milk powder and a buffering salt with a pH range of 5-8, to overcome stability issues and provide a stable, easy-to-reconstitute product.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Shape

If choline chloride is used as the choline source in solid composition, then the composition can be formulated as a solid powder, but the composition exhibits hygroscopicity and poor stability during manufacturing and storage

Engineering Contradiction:
Improvesolid powder formVSAvoidstability during manufacturing and storage
Core Design Contradiction:
ShapeVSStability of the object's composition

Solution Approach 1:

The patent changes the chemical form of choline from chloride to bitartrate salt, which fundamentally alters the hygroscopic properties and stability characteristics of the choline component in the solid composition

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite powder formulation combining choline bitartrate with milk proteins and buffering salts, where the interaction between components provides stability that individual components cannot achieve alone

Inventive Principle:
Principle #40Composite materials

2Quantity of substance

If milk proteins are combined with choline bitartrate in solid composition, then the composition provides complete nutritional profile, but the composition exhibits protein instability, phase separation, clumping, and poor reconstitution

Engineering Contradiction:
Improveprotein contentVSAvoidprotein stability and reconstitution properties
Core Design Contradiction:
Quantity of substanceVSStability of the object's composition

Solution Approach 1:

The patent adjusts the pH parameter by incorporating buffering salt components that maintain pH between 5-8, which optimizes protein stability and prevents phase separation and clumping in the solid composition

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The buffering salt acts as an intermediary component that mediates between choline bitartrate and milk proteins, preventing direct unfavorable interactions and maintaining overall composition stability

Inventive Principle:
Principle #24Intermediary (Mediator)

3Reliability

If liquid formulation is used for brain health supplement, then the composition provides good bioavailability, but the composition has high transport costs and inconvenient storage and distribution

Engineering Contradiction:
ImprovebioavailabilityVSAvoidtransport and storage convenience
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The patent transitions the composition from liquid phase to solid powder phase through lyophilization or spray drying, enabling convenient storage and transport while maintaining the bioavailability of active ingredients upon reconstitution

Inventive Principle:
Principle #36Phase transitions

Data Source

PatentUS20240316088A1Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases
Publication Date: 2024.09.26 NV NUTRICIA

AI summary

The invention pertains to a solid composition suitable for treating adult animals that suffer from brain-related disorders, brain-related decline or brain-related diseases, preferably suitable for treating adult animals that suffer from brain-related disorders, the composition containing (i) a uridine source, wherein the amount of the sum of all uridine sources, calculated on the basis of the weight of the molar equivalent of uridine monophosphate (UMP), is 0.3-15 g per 100 g dry weight of the composition, (ii) a polyunsaturated fatty acid, preferably an omega-3 polyunsaturated fatty acid, (iii) choline bitartrate, (iv) a buffering salt component, and (v) a milk protein source, wherein the milk protein source is a milk powder, and the buffering salt component containing at least one food approved salt, with a buffering capacity between pH 5-8, the buffering salt component preferably containing a mixture of food-approved salts, or a food-approved salt and its conjugated acid or base.